Safety and efficacy of direct-acting antiviral drugs in the treatment of chronic hepatitis C virus infection in patients with thalassemia: a prospective study

Abstract Background Hepatitis C virus (HCV) infection is a major cause of liver-related morbidity and mortality among thalassemic patients. Direct-acting antiviral agents (DAAs) are highly effective well-tolerated by chronic HCV Results The mean age our patients was 29 years. Sustained virologic response (SVR) at 12 24 weeks achieved in all (100%). most common side effects were fatigue (18%), anemia (13.63%), headache (4.5%). There no statistically significant difference the hemoglobin level before after treatment (p = 0.48). improvement serum bilirubin ALT levels compared to baseline data ( p < 0.0005 each). Conclusions DAAs, namely, sofosbuvir plus daclatasvir or ledipasvir, regimens with HCV.